Pomerantz LLP Investigates ORIC Pharmaceuticals for Securities Fraud
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 28 2026
0mins
Should l Buy ORIC?
Source: Globenewswire
- Securities Fraud Investigation: Pomerantz LLP is investigating whether ORIC Pharmaceuticals has engaged in securities fraud or other unlawful business practices, prompting investors to contact the firm for further information, highlighting serious concerns regarding corporate governance and transparency.
- Drug Efficacy Below Expectations: On March 31, 2026, ORIC announced that its prostate cancer treatment rinzimetostat (ORIC-944) is only as effective as a competitor, failing to meet market expectations for it to be the best in its class, which could adversely affect future sales and market share.
- Significant Stock Price Drop: Following the announcement, ORIC's stock price plummeted by $5.20, or 41%, closing at $7.48 on April 1, 2026, reflecting investor disappointment and a loss of confidence in the company's future prospects.
- Potential Legal Consequences: As a prominent securities litigation firm, Pomerantz LLP may provide legal support to affected investors, and if the investigation confirms fraudulent activities, ORIC could face substantial damages and reputational harm.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ORIC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ORIC
Wall Street analysts forecast ORIC stock price to rise
12 Analyst Rating
11 Buy
1 Hold
0 Sell
Strong Buy
Current: 8.810
Low
15.00
Averages
19.60
High
25.00
Current: 8.810
Low
15.00
Averages
19.60
High
25.00
About ORIC
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on improving patients’ lives by Overcoming Resistance In Cancer. The Company is advancing a diverse pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. The Company's clinical-stage product candidates include ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-114, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers. In addition, the Company is also developing multiple discovery stage precision medicines targeting other hallmark cancer resistance mechanisms. Its out-licensing candidates include ORIC-533 and ORIC-613.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pomerantz Investigates ORIC Pharmaceuticals for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating ORIC Pharmaceuticals and its executives for potential securities fraud or other unlawful business practices, which could undermine investor confidence and lead to legal repercussions.
- Drug Efficacy Below Expectations: On March 31, 2026, ORIC announced that its prostate cancer treatment rinzimetostat (ORIC-944) is only as effective as a competitor, failing to meet expectations of being the best in its class, which may impact its market competitiveness.
- Significant Stock Price Drop: Following this announcement, ORIC's stock price plummeted by $5.20, or 41%, closing at $7.48 per share on April 1, 2026, indicating market concerns regarding the company's future prospects.
- Potential Legal Consequences: Pomerantz LLP, recognized for its expertise in securities class actions, may provide legal support to affected investors, further exacerbating ORIC's legal and financial risks.
See More
Pomerantz LLP Investigates ORIC Pharmaceuticals for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating whether ORIC Pharmaceuticals has engaged in securities fraud or other unlawful business practices, prompting investors to contact the firm for further information, highlighting serious concerns regarding corporate governance and transparency.
- Drug Efficacy Below Expectations: On March 31, 2026, ORIC announced that its prostate cancer treatment rinzimetostat (ORIC-944) is only as effective as a competitor, failing to meet market expectations for it to be the best in its class, which could adversely affect future sales and market share.
- Significant Stock Price Drop: Following the announcement, ORIC's stock price plummeted by $5.20, or 41%, closing at $7.48 on April 1, 2026, reflecting investor disappointment and a loss of confidence in the company's future prospects.
- Potential Legal Consequences: As a prominent securities litigation firm, Pomerantz LLP may provide legal support to affected investors, and if the investigation confirms fraudulent activities, ORIC could face substantial damages and reputational harm.
See More
Pomerantz LLP Investigates Securities Fraud Claims Against ORIC Pharmaceuticals
- Securities Fraud Investigation: Pomerantz LLP is investigating whether ORIC Pharmaceuticals and its executives have engaged in securities fraud or other unlawful business practices, potentially impacting investor rights.
- Drug Efficacy Below Expectations: On March 31, 2026, ORIC announced that its prostate cancer treatment rinzimetostat (ORIC-944) is only as effective as a competitor, failing to meet expectations of being the best in its class, which may undermine market confidence.
- Significant Stock Price Drop: Following this news, ORIC's stock price fell by $5.20, or 41%, closing at $7.48 per share on April 1, 2026, reflecting investor concerns about the company's future prospects.
- Law Firm's Reputation: Pomerantz LLP is a prominent firm in securities and antitrust class litigation, founded over 85 years ago, dedicated to fighting for the rights of victims of securities fraud, showcasing its expertise and influence in such cases.
See More
US Stocks Close Higher Amid Optimism Over Middle East Conflict Resolution
- Market Rally: The S&P 500 rose by 0.72%, the Dow Jones increased by 0.48%, and the Nasdaq 100 climbed by 1.18%, reflecting growing investor optimism regarding a potential resolution to the Middle East conflict, which has bolstered market confidence.
- Strong Economic Data: The US ADP employment change for March increased by 62,000, surpassing expectations of 40,000, while February retail sales rose by 0.6% month-over-month, indicating robust economic recovery that could influence Federal Reserve policy decisions.
- Interest Rate Expectations: Despite positive economic indicators, hawkish comments from St. Louis Fed President raised concerns about inflation and employment, leading to a mere 1% chance of a 25 basis point rate hike at the upcoming April FOMC meeting, reflecting cautious market sentiment.
- Divergent Stock Performances: Target Hospitality surged over 36% after securing a multi-year contract worth over $550 million, while Nike fell more than 15% due to revenue forecasts indicating a decline, highlighting the market's varied outlook on different companies' futures.
See More
Oric Pharmaceuticals Shares Plunge 28% Amid Safety Concerns
- Significant Stock Drop: Oric Pharmaceuticals' shares plummeted 28% on Wednesday, marking the largest single-day decline in over four years, primarily due to investor concerns regarding the tolerability of its prostate cancer drug at higher doses, although analysts suggest the sell-off may be exaggerated.
- Dose Adjustment: Oric announced a shift to a lower 400 mg dose of its investigational drug Rinzimetostat, which demonstrated a more manageable safety profile compared to the previously tested 600 mg dose, with plans to advance to a global Phase 3 trial in the first half of 2026.
- Analyst Ratings Maintained: Jones Research maintained a ‘Buy’ rating on Oric with a $25 price target, noting that the drug's efficacy appears comparable to Pfizer's competing drug Mevrometostat while potentially offering a better safety profile, indicating continued market confidence in the stock.
- Market Sentiment Shift: Despite the sharp decline in stock price, retail sentiment shifted from ‘neutral’ to ‘extremely bullish’, reflecting optimism about Oric's future potential, with some users expressing that the stock has
See More
US Stocks Rise on Optimism Over Middle East Conflict Resolution
- Market Rally: The S&P 500 Index rose by 0.97%, the Dow Jones Industrial Average by 0.86%, and the Nasdaq 100 by 1.45%, reflecting growing investor confidence amid optimism that the Middle East conflict may soon conclude, which could stabilize global markets.
- Strong Economic Data: The US ADP employment change for March increased by 62,000, surpassing expectations of 40,000, while February retail sales rose by 0.6% month-over-month, indicating robust economic recovery that may influence Federal Reserve policy decisions.
- Interest Rate Outlook: Despite a mere 1% chance of a 25 basis point rate hike at the upcoming FOMC meeting, hawkish comments from St. Louis Fed President raised concerns about inflation and employment risks, potentially affecting investor sentiment and market dynamics.
- Divergent Stock Performances: Target Hospitality surged by over 37% after securing a multi-year contract worth over $550 million, while Nike fell by more than 13% due to revenue forecasts indicating a decline, highlighting varied market reactions to company-specific news.
See More
Pomerantz Investigates ORIC Pharmaceuticals for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating ORIC Pharmaceuticals and its executives for potential securities fraud or other unlawful business practices, which could undermine investor confidence and lead to legal repercussions.
- Drug Efficacy Below Expectations: On March 31, 2026, ORIC announced that its prostate cancer treatment rinzimetostat (ORIC-944) is only as effective as a competitor, failing to meet expectations of being the best in its class, which may impact its market competitiveness.
- Significant Stock Price Drop: Following this announcement, ORIC's stock price plummeted by $5.20, or 41%, closing at $7.48 per share on April 1, 2026, indicating market concerns regarding the company's future prospects.
- Potential Legal Consequences: Pomerantz LLP, recognized for its expertise in securities class actions, may provide legal support to affected investors, further exacerbating ORIC's legal and financial risks.
See More
Pomerantz LLP Investigates ORIC Pharmaceuticals for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating whether ORIC Pharmaceuticals has engaged in securities fraud or other unlawful business practices, prompting investors to contact the firm for further information, highlighting serious concerns regarding corporate governance and transparency.
- Drug Efficacy Below Expectations: On March 31, 2026, ORIC announced that its prostate cancer treatment rinzimetostat (ORIC-944) is only as effective as a competitor, failing to meet market expectations for it to be the best in its class, which could adversely affect future sales and market share.
- Significant Stock Price Drop: Following the announcement, ORIC's stock price plummeted by $5.20, or 41%, closing at $7.48 on April 1, 2026, reflecting investor disappointment and a loss of confidence in the company's future prospects.
- Potential Legal Consequences: As a prominent securities litigation firm, Pomerantz LLP may provide legal support to affected investors, and if the investigation confirms fraudulent activities, ORIC could face substantial damages and reputational harm.
See More
Pomerantz LLP Investigates Securities Fraud Claims Against ORIC Pharmaceuticals
- Securities Fraud Investigation: Pomerantz LLP is investigating whether ORIC Pharmaceuticals and its executives have engaged in securities fraud or other unlawful business practices, potentially impacting investor rights.
- Drug Efficacy Below Expectations: On March 31, 2026, ORIC announced that its prostate cancer treatment rinzimetostat (ORIC-944) is only as effective as a competitor, failing to meet expectations of being the best in its class, which may undermine market confidence.
- Significant Stock Price Drop: Following this news, ORIC's stock price fell by $5.20, or 41%, closing at $7.48 per share on April 1, 2026, reflecting investor concerns about the company's future prospects.
- Law Firm's Reputation: Pomerantz LLP is a prominent firm in securities and antitrust class litigation, founded over 85 years ago, dedicated to fighting for the rights of victims of securities fraud, showcasing its expertise and influence in such cases.
See More
US Stocks Close Higher Amid Optimism Over Middle East Conflict Resolution
- Market Rally: The S&P 500 rose by 0.72%, the Dow Jones increased by 0.48%, and the Nasdaq 100 climbed by 1.18%, reflecting growing investor optimism regarding a potential resolution to the Middle East conflict, which has bolstered market confidence.
- Strong Economic Data: The US ADP employment change for March increased by 62,000, surpassing expectations of 40,000, while February retail sales rose by 0.6% month-over-month, indicating robust economic recovery that could influence Federal Reserve policy decisions.
- Interest Rate Expectations: Despite positive economic indicators, hawkish comments from St. Louis Fed President raised concerns about inflation and employment, leading to a mere 1% chance of a 25 basis point rate hike at the upcoming April FOMC meeting, reflecting cautious market sentiment.
- Divergent Stock Performances: Target Hospitality surged over 36% after securing a multi-year contract worth over $550 million, while Nike fell more than 15% due to revenue forecasts indicating a decline, highlighting the market's varied outlook on different companies' futures.
See More
Oric Pharmaceuticals Shares Plunge 28% Amid Safety Concerns
- Significant Stock Drop: Oric Pharmaceuticals' shares plummeted 28% on Wednesday, marking the largest single-day decline in over four years, primarily due to investor concerns regarding the tolerability of its prostate cancer drug at higher doses, although analysts suggest the sell-off may be exaggerated.
- Dose Adjustment: Oric announced a shift to a lower 400 mg dose of its investigational drug Rinzimetostat, which demonstrated a more manageable safety profile compared to the previously tested 600 mg dose, with plans to advance to a global Phase 3 trial in the first half of 2026.
- Analyst Ratings Maintained: Jones Research maintained a ‘Buy’ rating on Oric with a $25 price target, noting that the drug's efficacy appears comparable to Pfizer's competing drug Mevrometostat while potentially offering a better safety profile, indicating continued market confidence in the stock.
- Market Sentiment Shift: Despite the sharp decline in stock price, retail sentiment shifted from ‘neutral’ to ‘extremely bullish’, reflecting optimism about Oric's future potential, with some users expressing that the stock has
See More
US Stocks Rise on Optimism Over Middle East Conflict Resolution
- Market Rally: The S&P 500 Index rose by 0.97%, the Dow Jones Industrial Average by 0.86%, and the Nasdaq 100 by 1.45%, reflecting growing investor confidence amid optimism that the Middle East conflict may soon conclude, which could stabilize global markets.
- Strong Economic Data: The US ADP employment change for March increased by 62,000, surpassing expectations of 40,000, while February retail sales rose by 0.6% month-over-month, indicating robust economic recovery that may influence Federal Reserve policy decisions.
- Interest Rate Outlook: Despite a mere 1% chance of a 25 basis point rate hike at the upcoming FOMC meeting, hawkish comments from St. Louis Fed President raised concerns about inflation and employment risks, potentially affecting investor sentiment and market dynamics.
- Divergent Stock Performances: Target Hospitality surged by over 37% after securing a multi-year contract worth over $550 million, while Nike fell by more than 13% due to revenue forecasts indicating a decline, highlighting varied market reactions to company-specific news.
See More
